Bulk Pharmaceutical API Sources for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
ASINEX		BAS 06989041
Aronis		ARONIS020379
NovoSeek		2764
Vitas-M Laboratory		STK021082

Bulk Active Pharmaceutical Ingredient (API) Sources for Cipro in Dextrose 5% in Plastic Container

Last updated: February 19, 2026

This report identifies key bulk Active Pharmaceutical Ingredient (API) manufacturers and suppliers for ciprofloxacin hydrochloride and dextrose monohydrate, essential components of Cipro in Dextrose 5% in Plastic Container. The analysis focuses on global supply chain dynamics, regulatory compliance, and critical quality attributes impacting sourcing decisions for pharmaceutical manufacturers.

What are the primary APIs for Cipro in Dextrose 5% in Plastic Container?

The primary Active Pharmaceutical Ingredients (APIs) for Cipro in Dextrose 5% in Plastic Container are:

• Ciprofloxacin Hydrochloride: The active antibacterial agent, a synthetic fluoroquinolone.
• Dextrose Monohydrate: A carbohydrate used as the vehicle or diluent in the intravenous solution.

These components are formulated into a sterile, ready-to-use intravenous infusion solution. The plastic container is typically a Flexible Infusion Container (FIC) made from materials like polyvinyl chloride (PVC) or non-PVC alternatives, designed for single use [1].

Who are the leading global manufacturers of Ciprofloxacin Hydrochloride API?

Global manufacturing of ciprofloxacin hydrochloride API is concentrated in Asia, with significant production capacity in India and China. Several manufacturers supply to regulated markets, adhering to stringent quality standards. Key considerations for selection include Good Manufacturing Practice (GMP) compliance, Drug Master File (DMF) status, and robust quality control systems.

Manufacturer Name	Country of Origin	GMP Certification	DMF Status (US FDA)	Annual Production Capacity (Estimated Metric Tons)
cipla Limited	India	Yes	Filed/Approved	50-100
Dr. Reddy's Laboratories	India	Yes	Filed/Approved	75-125
Sun Pharmaceutical Ind.	India	Yes	Filed/Approved	100-150
Lupin Limited	India	Yes	Filed/Approved	50-75
Aurobindo Pharma Limited	India	Yes	Filed/Approved	75-125
Zhejiang NHU Co., Ltd.	China	Yes	Filed/Approved	100-200
East China Pharmaceutical	China	Yes	Filed/Approved	75-125
Qilu Pharmaceutical Group	China	Yes	Filed/Approved	50-100
Zydus Cadila (Biologicals)	India	Yes	Filed/Approved	30-50
Hetero Drugs Limited	India	Yes	Filed/Approved	75-125

Note: Production capacities are estimates and subject to change. DMF status can refer to an active, approved, or pending application.

What are the key quality attributes for Ciprofloxacin Hydrochloride API?

Critical quality attributes (CQAs) for ciprofloxacin hydrochloride API are paramount for ensuring the safety and efficacy of the final drug product. These include:

• Purity: High purity is essential, with stringent limits on related substances and impurities, including process-related impurities and degradation products. USP and EP monographs define acceptable limits [2]. For example, the limit for any individual unspecified impurity in USP is typically not more than 0.10%.
• Chiral Purity: Ciprofloxacin is chiral, though typically used as a racemate. Ensuring consistent enantiomeric purity or ratio is important if a specific isomer is targeted.
• Particle Size Distribution (PSD): PSD affects dissolution rate and formulation homogeneity. Manufacturers often specify a median particle size (D50) and distribution range (e.g., D10, D90) to ensure consistent dissolution and processing behavior. Typical D50 values might range from 10 to 50 micrometers.
• Residual Solvents: Limits for residual solvents must comply with ICH Q3C guidelines. Common solvents used in synthesis include methanol, ethanol, isopropanol, and dichloromethane, each with defined acceptable daily intake (ADI) limits.
• Heavy Metals: Strict limits for heavy metals are enforced, typically not exceeding 10 ppm for total heavy metals as per USP/EP pharmacopeial standards.
• Water Content: Water content, usually determined by Karl Fischer titration, must be within specified limits to ensure API stability and prevent degradation. Typically, this is below 1.0%.
• Polymorphism: Ciprofloxacin hydrochloride can exist in different polymorphic forms. Consistent production of the desired polymorph is critical for solubility, stability, and bioavailability. Characterization is often done using X-ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC).

Who are the primary global suppliers of Dextrose Monohydrate API?

Dextrose monohydrate, a widely produced carbohydrate, is manufactured by numerous companies globally. The primary consideration for pharmaceutical use is USP/EP/JP grade quality, ensuring high purity and absence of microbial contamination. Suppliers must demonstrate compliance with pharmacopeial standards.

Supplier Name	Country of Origin	GMP Certification	Pharmacopeial Grade (USP/EP/JP)	Typical Purity
ADM (Archer Daniels)	USA	Yes	USP/EP/JP	>99.5%
Cargill, Incorporated	USA	Yes	USP/EP/JP	>99.5%
Ingredion Incorporated	USA	Yes	USP/EP/JP	>99.5%
Roquette Frères	France	Yes	USP/EP/JP	>99.5%
Tereos Syral	France	Yes	USP/EP/JP	>99.5%
Südzucker AG	Germany	Yes	USP/EP/JP	>99.5%
AGRANA Stärke GmbH	Austria	Yes	USP/EP/JP	>99.5%
Shaoxing County Shangyu	China	Yes	USP/EP/JP	>99.5%
Jilin Kanglong Biochem.	China	Yes	USP/EP/JP	>99.5%
COFCO Biochemical	China	Yes	USP/EP/JP	>99.5%

Note: Many suppliers may have GMP certifications applicable to food-grade products, but pharmaceutical manufacturers require specific confirmations of GMP for API production.

What are the key quality attributes for Dextrose Monohydrate API?

Quality attributes for pharmaceutical-grade dextrose monohydrate are focused on ensuring a sterile, safe, and chemically pure excipient for intravenous administration:

• Purity: Minimum purity of 99.5% on a dried basis is standard. Limits for related sugars (e.g., maltose, glucose oligomers) are strictly controlled.
• Absence of Endotoxins: For parenteral use, dextrose must be sterile and free from bacterial endotoxins. Manufacturers must demonstrate pyrogenicity testing compliance, with limits typically <0.5 EU/g for dextrose monohydrate.
• Heavy Metals: Similar to ciprofloxacin, limits for heavy metals are stringent, usually not exceeding 5 ppm.
• Water Content: Dextrose monohydrate has a defined water content (approx. 9-10% w/w). Deviations can impact solution osmolality and stability.
• pH: The pH of a standard solution (e.g., 10% w/v) must fall within a specified range, typically 3.5 to 6.5, to ensure compatibility with other components and physiological pH.
• Sulphated Ash: This measures inorganic impurities and is typically limited to not more than 0.1%.
• Microbial Limits: If not supplied as sterile, it must meet stringent microbial limits for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC), and absence of specified pathogens.

What are the regulatory requirements for API sourcing?

Pharmaceutical manufacturers must comply with rigorous regulatory requirements when sourcing APIs for Cipro in Dextrose 5% in Plastic Container.

• Drug Master Files (DMFs): For APIs intended for use in the US market, manufacturers typically file Type II DMFs with the U.S. Food and Drug Administration (FDA). These confidential documents provide detailed information on the API manufacturing process, facilities, and quality controls, allowing the FDA to review the API independently of the finished drug product application [3]. European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability (CEPs) serve a similar function in Europe.
• Good Manufacturing Practices (GMPs): API manufacturers must adhere to current GMP standards as defined by regulatory bodies such as the FDA (21 CFR Parts 210 & 211), European Medicines Agency (EMA), and other national health authorities. This includes rigorous quality management systems, facility controls, personnel training, and validation of processes.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines are critical. Key guidelines include ICH Q7 (GMP for APIs), ICH Q3A/B/C/D (Impurities in New Drug Substances/Products, Residual Solvents, Elemental Impurities), and ICH Q11 (Development and Manufacture of Drug Substances) [4].
• Supplier Audits: Pharmaceutical companies are required to conduct thorough audits of their API suppliers to verify GMP compliance, quality systems, and the security of the supply chain. These audits typically cover manufacturing processes, quality control laboratories, documentation, and regulatory compliance history.
• Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of the API throughout the supply chain are essential. This includes robust tracking and tracing mechanisms and secure packaging.
• Pharmacopeial Compliance: APIs must meet the current standards outlined in relevant pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP).

What are the challenges and considerations in API sourcing?

Sourcing APIs for complex formulations like Cipro in Dextrose 5% in Plastic Container presents several challenges.

• Supply Chain Volatility: Geopolitical events, natural disasters, and unexpected production issues at key manufacturing sites can lead to supply disruptions. Diversifying the supplier base across different geographic regions can mitigate this risk.
• Quality Consistency: Maintaining consistent API quality across different batches and suppliers is crucial. Robust incoming quality control testing and strong supplier relationships are vital.
• Cost Management: While quality is paramount, cost remains a significant factor. Negotiating favorable pricing with qualified suppliers while ensuring adherence to quality standards requires strategic sourcing.
• Regulatory Changes: Evolving regulatory requirements regarding impurities, elemental impurities, and environmental controls necessitate continuous monitoring and adaptation by both API manufacturers and finished product producers.
• Intellectual Property: While ciprofloxacin is off-patent, understanding any process patents or know-how associated with novel synthesis routes or purification methods can be important for some manufacturers.

Key Takeaways

• Ciprofloxacin hydrochloride and dextrose monohydrate are the primary APIs for Cipro in Dextrose 5% in Plastic Container.
• Major ciprofloxacin hydrochloride API manufacturers are concentrated in India and China, with a strong emphasis on GMP compliance and DMF filings.
• Pharmaceutical-grade dextrose monohydrate is widely available from global suppliers, with USP/EP/JP grade and endotoxin control being critical.
• Stringent adherence to GMP, ICH guidelines, pharmacopeial standards, and regulatory filings (DMFs/CEPs) is mandatory for API sourcing.
• Key API quality attributes include purity, impurity profiles, residual solvents, heavy metals, particle size (for ciprofloxacin), and endotoxin levels (for dextrose).
• Challenges in sourcing include supply chain volatility, maintaining quality consistency, cost pressures, and adapting to evolving regulatory landscapes.

Frequently Asked Questions

1. What is the typical shelf life for bulk Ciprofloxacin Hydrochloride API?

Typical shelf life for bulk ciprofloxacin hydrochloride API, when stored under recommended conditions (protected from light and moisture in well-closed containers), ranges from 3 to 5 years. Manufacturers provide specific expiry dates based on stability studies.

2. Are there any specific requirements for the plastic container material when used with Cipro in Dextrose 5%?

Yes, the plastic container material must be suitable for intravenous solutions and compatible with both ciprofloxacin hydrochloride and dextrose. Materials like PVC are common but may have leaching concerns. Non-PVC alternatives (e.g., polyolefins, EVA/PVC blends) are increasingly used. The container must be validated for leachables and extractables, ensuring no adverse interactions with the drug product or compromising its stability and safety [1].

3. How do regulatory agencies ensure the quality of APIs sourced globally?

Regulatory agencies like the FDA and EMA conduct routine inspections of API manufacturing facilities in foreign countries to ensure compliance with GMP standards. They also review DMFs and CEPs to assess the manufacturing processes and quality control measures of API suppliers. Import alerts can be issued for facilities found to be non-compliant.

4. What is the difference between USP and EP grade for Dextrose Monohydrate?

While both USP (United States Pharmacopeia) and EP (European Pharmacopoeia) grade dextrose monohydrate meet pharmaceutical standards, they are defined by different pharmacopeial monographs. Manufacturers must declare which pharmacopeial standard their product meets. For global markets, compliance with both or the specific regional standard is often required. Key differences may lie in specific test methods or impurity limits, although core quality requirements are generally aligned.

5. What are the implications of elemental impurities in API sourcing?

The introduction of ICH Q3D guideline on elemental impurities mandates that pharmaceutical manufacturers assess and control the risk of elemental impurities in their drug products. This requires API suppliers to identify potential elemental impurities arising from raw materials, manufacturing equipment, and processes. Manufacturers must then demonstrate that the levels of these impurities in the final drug product are within acceptable limits, often requiring close collaboration with API suppliers to manage risks upstream in the supply chain.

Citations

[1] U.S. Food and Drug Administration. (2020). Container Closure Systems for Packaging Small-Molecule Pharmaceutical Products. FDA Guidance for Industry. [2] United States Pharmacopeial Convention. (2023). The United States Pharmacopeia. [3] U.S. Food and Drug Administration. (2023). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines